Table 4.
Statistical analysis for the reduction in ulcer area
| Treatment | Mean ± SD | SE | Minimum/maximum | 95% confidence interval mean | P‐value | |
|---|---|---|---|---|---|---|
| Change from baseline – LOCF intent‐to‐treat population | ||||||
| AQUACEL® Ag/AQUACEL® (n = 141) | 49·65 ± 52·5 | 4·42 | −212·3/100 | 40·9 | 53·4 | |
| Urgotul® Silver/Urgotul® (n = 133) | 42·81 ± 60·0 | 5·2 | −217·7/100 | 32·5 | 53·1 | |
| Difference (1–2) | 6·84 ± 56·3 | 6·8 | −6·56 | 20·2 | 0·3158 | |
| Change from baseline – LOCF per protocol population | ||||||
| AQUACEL® Ag/AQUACEL® (n = 115) | 51·7 ± 52·9 | 4·9 | −212·3/100 | 41·9 | 61·5 | |
| Urgotul® Silver/Urgotul® (n = 104) | 45·1 ± 63·9 | 6·3 | −217·7/100 | 32·6 | 57·5 | |
| Difference (1–2) | 6·64 ± 58·4 | 7·9 | −9·1 | 22·4 | 0·4062 | |
LOCF, last observation carried forward.